The potential benefits of the mobilization of endogenous DC populations have further been strengthened by the report showing enhanced T cell and antibody responses upon the use of FMS-like tyrosine kinase 3 ligand (FLT3L), a known cytokine stimulating DC progenitors, in patients with resected melanoma [151,152,153]. This evidence concerns the gene FLT3LG and melanoma.